Theripio Innovations (the startup)

**What it means:** Theripio Innovations is the **startup company** founded by Dr. Christopher Cowan at MUSC to commercialize the MEF2C RNA therapeutic platform. In drug development, when academic researchers develop a promising therapy, they typically form a startup company to handle the transition from lab to clinic. This company will: - Handle intellectual property and patent filing - Seek additional funding (venture capital, partnerships) - Run clinical trials - Navigate FDA approval - Eventually bring the drug to market **Why this matters:** The formation of a dedicated startup is a **major milestone**. It means the research has progressed from "academic curiosity" to "commercially viable therapeutic program." Startups have a track record of being more agile and faster than academic institutions in moving therapies forward.